• Alternariol Triggers LX-2 Myofibroblast Transition in Liver

  2026-06-09

  This study provides the first omics-driven mechanistic evidence that Alternariol (AOH) and related Alternaria toxins directly induce hepatic stellate cell (LX-2) transdifferentiation into myofibroblasts, implicating them in liver fibrosis progression. The work maps core molecular pathways and proposes CotA laccase-based detoxification, advancing mycotoxin research and potential mitigation strategies.

• Fumagillin: Translational Strategies for Angiogenesis and Be

  2026-06-09

  This thought-leadership article explores the mechanistic, experimental, and translational dimensions of Fumagillin—a methionine aminopeptidase-2 inhibitor with dual antiangiogenic and antiparasitic potential. Blending evidence from oncology and aquatic disease models, it delivers actionable guidance for protocol design and strategic positioning of Fumagillin in cross-domain research, with a focus on differentiation and reproducibility.

• Blocking Extracellular Vesicle Release in Triple-Negative Br

  2026-06-08

  McNamee et al. conducted a comprehensive investigation into the inhibition of extracellular vesicle (EV) release in triple-negative breast cancer (TNBC), identifying that all EV subpopulations contribute to aggressive phenotypic transfer. Their study demonstrated that calpain inhibition—using Calpeptin among other agents—can reduce EV release by up to 98%, offering a robust approach to disrupt harmful intercellular communication in TNBC.

• Bestatin hydrochloride (A8621): Reliable Inhibition in Cell

  2026-06-08

  This article provides an in-depth, scenario-driven analysis of Bestatin hydrochloride (SKU A8621) for cell viability and cancer research workflows. Drawing on quantitative literature and validated product data, it guides biomedical researchers in optimizing assay reproducibility, interpreting results, and selecting reliable vendors. Explore protocol-focused best practices and actionable recommendations for using Bestatin hydrochloride from APExBIO.

• Fosinopril sodium: Reliable ACE Inhibition for Lab Assays

  2026-06-07

  This article addresses reproducibility and assay optimization challenges in cardiovascular disease models, focusing on Fosinopril sodium (SKU A4079). Through scenario-driven Q&A, we demonstrate how this ACE inhibitor supports robust, data-backed workflows for biomedical researchers.

• Nicotinamide Adenine Dinucleotide (NAD+): Beyond Energy, Tow

  2026-06-06

  Explore Nicotinamide Adenine Dinucleotide (NAD+) as more than a metabolic coenzyme—see how its regulation and signaling roles shape cellular adaptation under energy stress, featuring the latest mechanistic insights and practical implications for advanced biochemical research.

• Regulated Cell Death Pathways in Heart Disease: Mechanistic

  2026-06-05

  The reference paper systematically distinguishes between apoptosis and regulated necrosis in the context of heart disease, revealing that both forms of cell death are controlled by overlapping yet distinct molecular pathways. These insights highlight new potential targets for therapeutic intervention and deepen our understanding of cell fate decisions in cardiac pathology.

• Erastin: Redefining Ferroptosis for Translational Oncology

  2026-06-05

  Explore how Erastin, a pioneering ferroptosis inducer, is transforming cancer biology research and translational oncology. This article blends mechanistic insight with actionable guidance, addressing how Erastin targets RAS/BRAF-mutant tumor vulnerabilities, overcomes clinical drug resistance, and empowers next-generation oxidative stress assays. By integrating evidence from recent studies and expert protocols, we chart a strategic path for researchers seeking to leverage ferroptosis in the fight against refractory cancer.

• Entecavir (BMS200475): Benchmarks in Chronic Hepatitis B The

  2026-06-04

  Entecavir is a potent, selective HBV DNA polymerase inhibitor, clinically validated for chronic hepatitis B virus replication inhibition. It demonstrates high efficacy in both wild-type and lamivudine-resistant HBV, with a low resistance rate over long-term use. APExBIO provides Entecavir (BA1816) for research and translational applications.

• Tamsulosin Significantly Reduces Postoperative Urinary Reten

  2026-06-04

  This systematic review and meta-analysis provides robust evidence that perioperative tamsulosin administration halves the risk of postoperative urinary retention (POUR) without increasing adverse events. The findings offer mechanistic and translational insights valuable for both clinical and research applications in urological disease and smooth muscle physiology.

• Mechanisms of Cell Death in Heart Disease: Regulated Apoptos

  2026-06-03

  The reference study elucidates how both apoptosis and necrosis, traditionally viewed as distinct forms of cell death, share regulated and interconnected mechanisms in heart disease. These insights refine our understanding of myocardial injury and inform potential avenues for targeted therapeutic research.

• Fumagillin: Advanced Mechanisms and Protocol Design for MetA

  2026-06-03

  Explore the advanced mechanisms of Fumagillin as a methionine aminopeptidase-2 inhibitor. This in-depth guide uniquely integrates comparative efficacy, molecular insights, and protocol design strategies for angiogenesis and antiparasitic research.

• Hyperthermia and Cisplatin Synergize via Caspase-8 Activatio

  2026-06-02

  The referenced study demonstrates that combining hyperthermia with cisplatin promotes caspase-8 accumulation and activation, enhancing both apoptosis and pyroptosis in cancer cells. These findings elucidate a key mechanism underlying combination therapies and highlight the therapeutic potential of targeting caspase-8 in cancer treatment.

• Lisinopril Dihydrate in Hypertension Research: Applied ACE I

  2026-06-02

  Lisinopril dihydrate stands apart as a highly selective, long-acting ACE inhibitor, enabling precision in hypertension, heart failure, and nephropathy models. This guide demystifies its experimental integration, protocol enhancements, and troubleshooting—empowering researchers to maximize reproducibility and translational value.

• D-Luciferin in Metastasis Research: Precision Tools for In V

  2026-06-01

  Explore how D-Luciferin, a leading firefly luciferase substrate, enables advanced, quantitative in vivo imaging of metastatic colorectal cancer. This article reveals unique protocol insights and translational relevance not covered elsewhere.

15353 records 1/1024 page Next 12345 下5页 Last page